CSIMarket
 


Ngm Biopharmaceuticals Inc   (NGM)
Other Ticker:  
 

Ngm Biopharmaceuticals Inc 's Working Capital Ratio

NGM's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the forth quarter 2023, Working Capital Ratio deteriorated to 7.79 below Ngm Biopharmaceuticals Inc 's average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Working Capital Ratio than Ngm Biopharmaceuticals Inc in forth quarter 2023. While Working Capital Ratio total ranking in the forth quarter 2023 has deteriorated compared to the prior quarter from 216 to 268.

Explain Working Capital Ratio
How much in Current Assets NGM´s has?
What is the value of NGM´s Current Liabilities?


NGM Working Capital Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -58.03 % -54.02 % -33.18 % -14.95 % -22.02 %
Y / Y Current Assets Change -45.84 % -43.92 % -35.89 % -28.17 % -23.84 %
Working Capital Ratio MRQ 7.79 7.92 7.19 6.4 6.04
NGM's Total Ranking # 268 # 216 # 389 # 201 # 328
Seq. Current Liabilities Change -10.13 % -21.38 % -25.01 % -20.77 % -1.55 %
Seq. Current Assets Change -11.63 % -13.39 % -15.72 % -16.04 % -8.5 %



Working Capital Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 47
Healthcare Sector # 86
Overall Market # 268


Working Capital Ratio Statistics
High Average Low
17.36 9.11 6.04
(Jun 30 2019)   (Dec 31 2022)




Financial Statements
Ngm Biopharmaceuticals Inc 's Current Liabilities $ 20 Millions Visit NGM's Balance sheet
Ngm Biopharmaceuticals Inc 's Current Assets $ 156 Millions Visit NGM's Balance sheet
Source of NGM's Sales Visit NGM's Sales by Geography


Cumulative Ngm Biopharmaceuticals Inc 's Working Capital Ratio

NGM's Working Capital Ratio for the trailling 12 Months

NGM Working Capital Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -58.03 % -54.02 % -33.18 % -14.95 % -22.02 %
Y / Y Current Assets TTM Growth -45.84 % -43.92 % -35.89 % -28.17 % -23.84 %
Working Capital Ratio TTM 7.18 6.69 6.46 6.59 6.87
Total Ranking TTM # 198 # 481 # 546 # 617 # 686
Seq. Current Liabilities TTM Growth -10.13 % -21.38 % -25.01 % -20.77 % -1.55 %
Seq. Current Assets TTM Growth -11.63 % -13.39 % -15.72 % -16.04 % -8.5 %


On the trailing twelve months basis Current Liabilities decreased faster than Ngm Biopharmaceuticals Inc 's average Current Assets, this led to increase in in Ngm Biopharmaceuticals Inc 's Working Capital Ratio to 7.18, Working Capital Ratio remained below NGM average.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 209 other companies have achieved higher Working Capital Ratio than Ngm Biopharmaceuticals Inc . While Working Capital Ratio overall ranking has improved so far to 131, from total ranking during the twelve months ending third quarter 2023 at 2352.

Explain Working Capital Ratio
How much in Current Assets NGM´s has?
What is the value of NGM´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 210
Healthcare Sector # 477
Within the Market # 268


trailing twelve months Working Capital Ratio Statistics
High Average Low
9.7 7.89 6.46
(Jun 30 2020)   (Jun 30 2023)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Diamedica Therapeutics Inc   19.86 $ 53.675  Millions$ 2.703  Millions
Edgewise Therapeutics inc   19.50 $ 326.997  Millions$ 16.771  Millions
Structure Therapeutics Inc   19.14 $ 473.608  Millions$ 24.740  Millions
Sagimet Biosciences inc   17.29 $ 96.646  Millions$ 5.589  Millions
Protagonist Therapeutics inc   16.71 $ 355.577  Millions$ 21.274  Millions
Nextcure Inc   16.38 $ 112.725  Millions$ 6.883  Millions
Royalty Pharma Plc  16.29 $ 1,274.193  Millions$ 78.222  Millions
Lyell Immunopharma Inc   16.07 $ 554.686  Millions$ 34.519  Millions
Agios Pharmaceuticals Inc   15.75 $ 833.835  Millions$ 52.947  Millions
Anixa Biosciences Inc   15.19 $ 25.219  Millions$ 1.660  Millions
Keros Therapeutics Inc   14.25 $ 347.293  Millions$ 24.373  Millions
Compass Pathways Plc  13.33 $ 261.296  Millions$ 19.604  Millions
Vyne Therapeutics Inc   12.73 $ 95.963  Millions$ 7.538  Millions
Rallybio Corporation  12.39 $ 114.789  Millions$ 9.263  Millions
Rezolute Inc   12.00 $ 96.085  Millions$ 8.008  Millions
Immuneering Corporation  11.81 $ 89.084  Millions$ 7.545  Millions
Cryoport inc   11.77 $ 536.792  Millions$ 45.610  Millions
Cassava Sciences Inc  11.62 $ 129.633  Millions$ 11.158  Millions
Virios Therapeutics Inc   11.62 $ 4.165  Millions$ 0.359  Millions
Anaptysbio Inc   11.41 $ 406.835  Millions$ 35.665  Millions
Vanda Pharmaceuticals Inc   11.26 $ 432.946  Millions$ 38.460  Millions
Prothena Corporation Public Limited Company  11.24 $ 639.282  Millions$ 56.891  Millions
Cymabay Therapeutics Inc   10.96 $ 403.802  Millions$ 36.843  Millions
Ovid Therapeutics Inc   10.72 $ 109.598  Millions$ 10.228  Millions
Spyre Therapeutics Inc   10.68 $ 341.528  Millions$ 31.978  Millions
Chimerix Inc   10.25 $ 189.110  Millions$ 18.443  Millions
Aprea Therapeutics Inc   10.24 $ 22.521  Millions$ 2.199  Millions
Milestone Pharmaceuticals inc   10.11 $ 73.032  Millions$ 7.226  Millions
Summit Therapeutics Inc   9.30 $ 189.712  Millions$ 20.405  Millions
Ac Immune Sa  9.22 $ 125.153  Millions$ 13.576  Millions

Date modified: 2024-03-12T09:10:52+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com